GlassScriptPhysician profile
Sabu George
NPI 1265496723
$3,066.83
in general payments reported to CMS, 2019-2025
18 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,419 · 2020: $537 · 2021: $246 · 2022: $152 · 2023: $412 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $713.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $712.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.99 | 2019-2025 | |
| Gilead Sciences, INC. | $346.00 | 2019-2021 | |
| Janssen Biotech, INC. | $275.53 | 2019-2023 | Simponi Aria, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.59 | 2019-2023 | Xifaxan |
| Pfizer INC. | $205.90 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $182.06 | 2019-2020 | |
| Madrigal Pharmaceuticals | $130.20 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $125.55 | 2023 | Zeposia |
| Braintree Laboratories, INC. | $118.81 | 2019 | |
| Boston Scientific Corporation | $107.75 | 2019 | |
| Janssen Scientific Affairs, LLC | $93.84 | 2019 | |
| Redhill Biopharma INC. | $67.42 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $63.60 | 2019-2020 | |
| Organon LLC | $39.99 | 2025 | Vtama |
| Allergan, INC. | $32.95 | 2019-2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $19.67 | 2019 | |
| Medtronic, INC. | $19.36 | 2022 | |
| Qol Medical, LLC | $12.62 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sabu George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.